What if aging is not a collection of diseases, but a system-level failure we can intervene in?
In this episode of Galaxy Balance, Cory Smith sits down with Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, to explore a new approach to longevity rooted in gene therapy and systems biology.
Noah’s work focuses on treating aging at its source by rebalancing key biological pathways across the body. Instead of targeting one disease at a time, his team is developing combination gene therapies designed to improve function across multiple organs simultaneously.
Rejuvenate Bio is currently raising on Wefunder. This is a rare opportunity to invest in a scaling biotech on the same terms as their VC partners. If our conversation resonated with you, this is your chance to join what Dr. Noah Davidsohn is building. Learn more and invest at wefunder.com/rejuvenatebio
00:00 - Replacing organs to reverse aging: science fiction or imminent reality
00:34 - Welcome to Galaxy Balance: exploring biology and AI frontiers
01:01 - Noah Davidson’s background and mission at Rejuvenate Bio
01:57 - Reprogramming biological systems for systemic healthspan extension
02:41 - The influence of sci-fi on Noah’s interest in space and longevity
03:38 - Space exploration's crossover with biological resilience
05:25 - The societal impact of science fiction on technological progress
07:55 - Addressing dystopian themes in modern sci-fi and their societal reflection
08:16 - The absence of longevity-focused sci-fi and Noah’s motivation
09:12 - Personal story: pet dog inspired Noah’s longevity work
10:33 - Origin of Rejuvenate Bio and its mission to treat aging
11:57 - Combining gene therapies targeting multiple age-related diseases
13:44 - The potential and limitations of epigenetic partial reprogramming
14:14 - Upcoming clinical trials and safety considerations for gene therapy
16:01 - Cyclic gene therapy and risks of permanent expression
17:43 - Inducible gene expression systems: safety and practical considerations
21:19 - Systemic, liver-targeted gene therapies: permanent vs. transient
22:33 - Strategies for pet therapies and expanding to human applications
25:47 - Manufacturing innovations reducing costs for wide-scale treatment
27:12 - Prophylactic use of gene therapies in pets and humans
29:08 - Targeting multiple diseases with a single systemic therapy
30:40 - Breeds at risk for mitral valve disease and targeted therapy efforts
33:42 - Disease-modifying treatments for fibrosis and heart failure
36:48 - How AAV vector delivery works and safety measures in tissue targeting
42:47 - Regulatory pathways for animal therapies and translational relevance
44:22 - Challenges in funding and VC environment for longevity startups
45:45 - The strategy of using animal models as a bridge to human therapies
50:05 - Future scientific directions: partial reprogramming and cell replacement tech
52:37 - The concept of longevity escape velocity and current progress
53:44 - Personal longevity practices: exercise, diet, sleep, stress management
55:27 - The role of biometric feedback devices in health monitoring
56:54 - Emerging modalities and innovative approaches in anti-aging research
58:24 - The ship of Theseus analogy for cell and tissue replacement
59:37 - Philosophical questions about consciousness and identity in aging
1:00:43 - Recommended sci-fi books for longevity and biotech enthusiasts
1:01:39 - Career advice for aspiring scientists and interdisciplinary innovation
1:02:45 - Wrap-up and best wishes for ongoing longevity breakthroughs
